[go: up one dir, main page]

ZA772433B - Polypeptide - Google Patents

Polypeptide

Info

Publication number
ZA772433B
ZA772433B ZA00772433A ZA772433A ZA772433B ZA 772433 B ZA772433 B ZA 772433B ZA 00772433 A ZA00772433 A ZA 00772433A ZA 772433 A ZA772433 A ZA 772433A ZA 772433 B ZA772433 B ZA 772433B
Authority
ZA
South Africa
Prior art keywords
polypeptide
Prior art date
Application number
ZA00772433A
Other languages
English (en)
Inventor
A Dutta
M Giles
B Furr
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of ZA772433B publication Critical patent/ZA772433B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA00772433A 1976-05-11 1977-04-22 Polypeptide ZA772433B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB19327/76A GB1524747A (en) 1976-05-11 1976-05-11 Polypeptide

Publications (1)

Publication Number Publication Date
ZA772433B true ZA772433B (en) 1978-03-29

Family

ID=10127509

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA00772433A ZA772433B (en) 1976-05-11 1977-04-22 Polypeptide

Country Status (27)

Country Link
US (1) US4100274A (de)
JP (1) JPS52136172A (de)
AT (2) AT379400B (de)
AU (1) AU508025B2 (de)
BE (1) BE854467A (de)
BG (1) BG60740B2 (de)
CA (1) CA1101844A (de)
CH (2) CH627151A5 (de)
CS (1) CS199673B2 (de)
DD (1) DD136738A5 (de)
DE (1) DE2720245C2 (de)
DK (1) DK149596C (de)
ES (1) ES458691A1 (de)
FI (1) FI64139C (de)
FR (1) FR2351092A1 (de)
GB (1) GB1524747A (de)
HU (1) HU179990B (de)
IE (1) IE44426B1 (de)
IL (1) IL52014A (de)
NL (2) NL191793C (de)
NO (2) NO147304C (de)
NZ (1) NZ183931A (de)
PL (2) PL104362B1 (de)
SE (2) SE437837B (de)
SU (1) SU910116A3 (de)
YU (1) YU40672B (de)
ZA (1) ZA772433B (de)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
JPH0284272U (de) * 1988-12-20 1990-06-29
JP2672677B2 (ja) * 1989-02-09 1997-11-05 タツプ・フアーマシユーテイカルズ・インコーポレイテツド Ｌｈｒｈ同族体
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
IL93693A (en) * 1989-03-10 2000-01-31 Endorech Inc Pharmaceutical compositions for the treatment of estrogen sensitive diseases
GR1001164B (el) * 1989-07-07 1993-05-24 Endorecherche Inc Παραγωγα αρρενογονου ορμονης προς χρησιν εις την αναστολην δραστηριοτητος της στεροειδους ορμονης φυλου
DK0595796T3 (da) * 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
GB9112859D0 (en) * 1991-06-14 1991-07-31 Ici Plc Peptide process
TW239145B (de) * 1992-05-21 1995-01-21 Endorech Inc
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
EP1008656A4 (de) 1996-06-13 2000-09-20 Itoham Foods Inc Verfahren zur herstellung von lh-rh derivaten
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
EP3143995B2 (de) 2001-02-19 2025-01-15 Novartis Pharma AG Ein rapamycinderivat zur behandlung von lungenkrebs
CN1700917B (zh) 2001-05-16 2010-04-28 诺瓦提斯公司 含n-(5-{4-[4-甲基-(1-哌嗪基)甲基]-苯甲酰氨基}-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶-胺和化疗药的联合形式
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003240655B2 (en) 2002-05-16 2007-09-06 Novartis Ag Use of EDG receptor binding agents in cancer
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
WO2004054542A2 (en) * 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
EP1735307B1 (de) 2004-04-07 2012-08-29 Novartis AG Iap-inhibitoren
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2113513B1 (de) * 2004-06-25 2016-05-18 Takeda Pharmaceutical Company Limited Metastinderivate und deren Verwendung
EP3103477A1 (de) * 2004-09-17 2016-12-14 Durect Corporation Anhaltende lokalanästhetikumzusammensetzung mit saib
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
RU2436575C2 (ru) * 2005-01-21 2011-12-20 Астекс Терапьютикс Лимитед Соединения для использования в фармацевтике
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
EP1773870B1 (de) 2005-05-03 2009-12-16 Novetide Ltd. Verfahren zur herstellung von peptidderivaten
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AR058065A1 (es) 2005-09-27 2008-01-23 Novartis Ag Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
CN101443002B (zh) 2006-05-09 2012-03-21 诺瓦提斯公司 包含铁螯合剂和抗肿瘤药的组合及其用途
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
EP2120900A2 (de) 2007-02-15 2009-11-25 Novartis AG Kombinationen von lb589 mit anderen therapeutischen wirkstoffen zur krebsbehandlung
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
BRPI0908603A2 (pt) 2008-03-24 2020-08-18 Novartis Ag inibidores de metaloprotease de matriz com base em arilsulfonamida.
JP5330498B2 (ja) 2008-03-26 2013-10-30 ノバルティス アーゲー 脱アセチル化酵素ｂのヒドロキサメートを基にした阻害剤
US20100260844A1 (en) * 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
RU2519673C2 (ru) * 2008-11-28 2014-06-20 Новартис Аг Комбинации ингибитора hsp90
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
EA021011B1 (ru) 2009-06-26 2015-03-31 Новартис Аг 1,3-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗОЛИДИН-2-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ Cyp 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
EP2467383A1 (de) 2009-08-20 2012-06-27 Novartis AG Heterocyclische oximverbindungen
WO2011023677A1 (en) 2009-08-26 2011-03-03 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
EA201200471A1 (ru) 2009-09-10 2012-10-30 Новартис Аг Простые эфирные производные бициклических гетероарилов
EP2496575B1 (de) 2009-11-04 2014-04-30 Novartis AG Heterocyclische sulfonamidderivate als mek-hemmer
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
JP5456908B2 (ja) 2009-12-08 2014-04-02 ノバルティス アーゲー ヘテロ環式スルホンアミド誘導体
WO2012168884A1 (en) 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
MX2012014579A (es) 2010-06-16 2013-05-22 Endorech Inc Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos.
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
EP2673277A1 (de) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
EP2683722A1 (de) 2011-03-08 2014-01-15 Novartis AG Bicyclische fluorphenyl-heteroarylverbindungen
WO2012149413A1 (en) 2011-04-28 2012-11-01 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
JP2014513727A (ja) 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
SG195067A1 (en) 2011-06-27 2013-12-30 Novartis Ag Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
BR112014006223A8 (pt) 2011-09-15 2018-01-09 Novartis Ag 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação
EP2785717B1 (de) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidinverbindungen
DK2794600T3 (en) 2011-12-22 2018-03-12 Novartis Ag -2,3-Dihydro-benzo [1,4] oxazine derivatives and related compounds such as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of rheumatoid arthritis
EP2794594A1 (de) 2011-12-22 2014-10-29 Novartis AG Chinolinderivate
BR112014015339A2 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com parceiros de ligação
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
JP2015503515A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物および組成物
KR20140107575A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
EP2794589A1 (de) 2011-12-23 2014-10-29 Novartis AG Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
JO3357B1 (ar) 2012-01-26 2019-03-13 Novartis Ag مركبات إيميدازوبيروليدينون
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
BR112014031421A2 (pt) 2012-06-15 2017-06-27 Brigham & Womens Hospital Inc composições para tratamento de câncer e métodos para produção das mesmas
CN104520297B (zh) 2012-08-13 2016-08-24 瑞士诺华动物保健有限公司 作为肾酪氨酸激酶抑制剂的双环杂芳基环烷基二胺衍生物
PE20150998A1 (es) 2012-10-02 2015-06-29 Epitherapeutics Aps Inhibidores de histona demetilasas
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
SG10201707027SA (en) 2013-02-27 2017-09-28 Epitherapeutics Aps Inhibitors of histone demethylases
EP2983468A4 (de) 2013-03-15 2016-09-07 Durect Corp Zusammensetzungen mit rheologiemodifikator zur reduzierung der auflösungsvariabilität
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
AU2014321419B2 (en) 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
BR112016012141A2 (pt) 2014-01-15 2017-08-08 Novartis Ag "combinações farmacêuticas, uso das mesmas, e embalagem comercial"
EP3122730B1 (de) 2014-03-28 2020-03-25 Calitor Sciences, LLC Substituierte heteroarylverbindungen und verfahren zur verwendung davon
TW201625535A (en) 2014-03-31 2016-07-16 Epitherapeutics Aps Inhibitors of histone demethylases
JP2017513931A (ja) 2014-04-03 2017-06-01 インビクタス オンコロジー ピーヴィティー．リミテッド 超分子コンビナトリアル治療薬
MA40470A (fr) 2014-08-27 2016-03-03 Gilead Sciences Inc Composés et procédés d'inhibition des histones déméthylases
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AU2017292791B2 (en) 2016-07-06 2023-05-25 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
EP3730483B1 (de) 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Klasse von pyrimidinderivaten als kinaseinhibitoren
JP7450541B2 (ja) 2018-01-20 2024-03-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換アミノピリミジン化合物及び使用方法
EP4034078A4 (de) * 2019-09-26 2023-09-20 S.I.S. Shulov Innovative Science Ltd. Anti-aging-zusammensetzungen und verfahren zur verwendung
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
JPS50142563A (de) * 1974-04-26 1975-11-17
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US3971737A (en) * 1975-03-24 1976-07-27 American Home Products Corporation [2-Methyl-Ala6 ]LRH
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4024121A (en) * 1976-01-27 1977-05-17 Schally Andrew Victor (Pyro)-Glu-His-Trp-D-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHR and intermediates
US4018726A (en) * 1975-06-12 1977-04-19 Andrew Victor Schally [D-Phe6 ]-LH-RH and intermediates therefor
US3992530A (en) * 1975-12-08 1976-11-16 American Home Products Corporation [D-2-(1,4-Cyclohexadienyl)gly]6 -des-gly10 -lrh nonapeptide amides

Also Published As

Publication number Publication date
IE44426B1 (en) 1981-11-18
DK149596B (da) 1986-08-04
CH627151A5 (de) 1981-12-31
NO147304B (no) 1982-12-06
YU40672B (en) 1986-04-30
HU179990B (en) 1983-01-28
DK149596C (da) 1987-01-05
PL108860B1 (en) 1980-05-31
DE2720245A1 (de) 1977-11-24
DE2720245C2 (de) 1986-09-25
SE7705432L (sv) 1977-11-12
FI771480A7 (de) 1977-11-12
ES458691A1 (es) 1978-08-16
SE437837B (sv) 1985-03-18
ATA217979A (de) 1981-06-15
AT365562B (de) 1982-01-25
FR2351092B1 (de) 1980-02-22
BG60740B2 (bg) 1996-01-31
CH629475A5 (de) 1982-04-30
DK207977A (da) 1977-11-12
SE437993B (sv) 1985-03-25
CS199673B2 (en) 1980-07-31
PL197889A1 (pl) 1978-02-13
NO822984L (no) 1977-11-14
IL52014A (en) 1979-11-30
AU508025B2 (en) 1980-03-06
PL104362B1 (pl) 1979-08-31
US4100274A (en) 1978-07-11
JPS6113480B2 (de) 1986-04-14
FI64139B (fi) 1983-06-30
ATA335877A (de) 1985-05-15
AT379400B (de) 1985-12-27
SU910116A3 (ru) 1982-02-28
BE854467A (fr) 1977-11-10
FI64139C (fi) 1983-10-10
FR2351092A1 (fr) 1977-12-09
IE44426L (en) 1977-11-11
JPS52136172A (en) 1977-11-14
GB1524747A (en) 1978-09-13
NL970002I2 (nl) 1997-05-01
CA1101844A (en) 1981-05-26
NL7705130A (nl) 1977-11-15
NO147304C (no) 1983-03-16
NL970002I1 (nl) 1997-03-03
NO149586B (no) 1984-02-06
NZ183931A (en) 1979-03-16
SE8007763L (sv) 1980-11-05
NL191793B (nl) 1996-04-01
NO149586C (no) 1984-05-16
NO771644L (no) 1977-11-14
AU2468177A (en) 1978-11-02
YU117277A (en) 1983-02-28
DD136738A5 (de) 1979-07-25
NL191793C (nl) 1996-08-02
IL52014A0 (en) 1977-07-31

Similar Documents

Publication Publication Date Title
ZA772433B (en) Polypeptide
GB1547911A (en) Polypeptides
AU517514B2 (en) 3-de-0-methylfortimicins
AU2542577A (en) 4-amino-4-arylcyclohexanones
HK27584A (en) Peptides
AU2384277A (en) Triazolo-pyrimidines
CS40277A2 (en) Zarovzdorna soucast pro nadoby obsahujici taveninu kovu
AU513702B2 (en) Peptides
AU3191677A (en) Cyclopentan-1-amine
AU2726877A (en) Benzofuranyl-benzimidazoles
AU507260B2 (en) N-2-imidazolidinylidene-benzeneamine
AU2451277A (en) Isothiazolopyridines
AU2714177A (en) Phenoxy-hydroxypropylamines
AU2727977A (en) Peptides
AU503893B2 (en) Polypeptide
AU1309176A (en) Fire-barriers
ZA771789B (en) Polypeptide
CS886177A2 (en) Nabijeci zarizeni pro automatickou strelnou zbran
JPS53111060A (en) Alphaaaminoxyacyl grouppcontaining peptide
JPS52121455A (en) Toothhbruching things
AU2893177A (en) Perhydroindolinols
AU508067B2 (en) Electroradiography
AU2493077A (en) 2-amino-substituted-isothioureido bewzenes
AU2378777A (en) Amino - alkoxyalkanes
AU2710877A (en) Benzodioxepins